Literature DB >> 7960417

Clinical results with three different kinds of small optic PMMA-IOLs.

M Amon1, R Menapace, U Radax, P Papapanos.   

Abstract

In this prospective study the clinical results using three different small optic IOLs are presented. The best results were achieved in those cases with an anterior capsule rim overlapping the entire optic periphery. In those cases with sulcus fixation, haptic in/out and optic in/out positions a higher percentage of capsule fibrosis (Soemmering's rings) was documented (sulcus fixation: 100%, haptic in/out position: 75%, optic in/out position: 65.5%, bag: 7.3%). The fibrosis developed because of contact between the anterior and the posterior capsule leaf. These cases also showed decentrations of the intraocular lens (IOL) more often (sulcus fixation: 50%, haptic in/out position: 75%, optic in/out position: 34.5%, bag: 31.7%). Only one patient was disturbed by glare and halo phenomenons. Cellular reactions on the lens surface were moderate in most cases. Differences specific to lens type were found between the three IOLs implanted. The clinical results were comparable to the results of other comprehensive IOL studies. Under certain indication small optic IOLs represent an alternative to flexible implants for small incision surgery.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7960417     DOI: 10.1007/BF00919407

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  12 in total

1.  Evaluation of 200 consecutive IOGEL 1103 capsular-bag lenses implanted through a small incision.

Authors:  R Menapace; M Amon; U Radax
Journal:  J Cataract Refract Surg       Date:  1992-05       Impact factor: 3.351

2.  Use of small incisions to control induced astigmatism and inflammation following cataract surgery.

Authors:  J P Gills; D R Sanders
Journal:  J Cataract Refract Surg       Date:  1991       Impact factor: 3.351

3.  Observation of blood-aqueous barrier function after posterior chamber intraocular lens implantation.

Authors:  T Kaiya
Journal:  J Cataract Refract Surg       Date:  1990-05       Impact factor: 3.351

4.  Advantages and limitations of current soft intraocular lenses.

Authors:  A C Neumann; B Cobb
Journal:  J Cataract Refract Surg       Date:  1989-05       Impact factor: 3.351

5.  Posterior chamber intraocular lenses in a series of 75 autopsy eyes. Part I: Loop location.

Authors:  D J Apple; S B Park; K H Merkley; R N Brems; S C Richards; K E Langley; K L Piest; R A Isenberg
Journal:  J Cataract Refract Surg       Date:  1986-07       Impact factor: 3.351

Review 6.  Soft intraocular lenses.

Authors:  L Allarakhia; R L Knoll; R L Lindstrom
Journal:  J Cataract Refract Surg       Date:  1987-11       Impact factor: 3.351

7.  Cellular invasion on the surface of intraocular lenses. In vivo cytological observations following lens implantation.

Authors:  M Wenzel; M Reim; M Heinze; A Böcking
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

8.  Posterior capsule opacification in pseudophakic eyes.

Authors:  P J McDonnell; M A Zarbin; W R Green
Journal:  Ophthalmology       Date:  1983-12       Impact factor: 12.079

9.  [Perilenticular tissue changes in intraocular lenses worn without complications].

Authors:  B Daicker
Journal:  Klin Monbl Augenheilkd       Date:  1984-05       Impact factor: 0.700

10.  Cellular invasion on hydrogel and poly(methyl methacrylate) implants. An in vivo study.

Authors:  M Amon; R Menapace
Journal:  J Cataract Refract Surg       Date:  1991-11       Impact factor: 3.351

View more
  2 in total

Review 1.  Surface chemistry influences implant biocompatibility.

Authors:  Paul Thevenot; Wenjing Hu; Liping Tang
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

2.  Surface chemistry influences implant-mediated host tissue responses.

Authors:  Shwetha Kamath; Dhiman Bhattacharyya; Chandana Padukudru; Richard B Timmons; Liping Tang
Journal:  J Biomed Mater Res A       Date:  2008-09       Impact factor: 4.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.